AI assistant
Aura Biosciences, Inc. — Director's Dealing 2021
Oct 29, 2021
33080_dirs_2021-10-29_74ed7357-ac9a-480b-a5c6-24f61b74df8c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aura Biosciences, Inc. (AURA)
CIK: 0001501796
Period of Report: 2021-10-28
Reporting Person: Rich Cadmus (See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-10-28 | Common Stock | A | 26250 | $0.00 | Acquired | 26250 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-10-28 | Stock Option (Right to Buy) | $14.00 | A | 112500 | Acquired | 2031-10-27 | Common stock (112500) | Direct |
Footnotes
F1: These shares were acquired pursuant to a restricted stock unit award under the Company's 2021 Stock Option and Incentive Plan. Each restricted stock unit represents the right to receive one share of the Company's common stock. These restricted stock units vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant.
F2: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 28, 2021 with the remainder vesting thereafter pro-rata in 36 monthly installments.